Vascular Biogenics Ltd. – NASDAQ:VBLT
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 2 days
Vascular Biogenics Ltd. stock price monthly change
-33.33%
month
Vascular Biogenics Ltd. stock price quarterly change
-33.65%
quarter
Vascular Biogenics Ltd. stock price yearly change
+19.08%
year
Vascular Biogenics Ltd. key metrics
Market Cap | 12.11M |
Enterprise value | N/A |
P/E | -0.43 |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | 15.06 |
Price/Book | 0.57 |
PEG ratio | N/A |
EPS | -0.16 |
Revenue | N/A |
EBITDA | -15.58M |
Income | -12.58M |
Revenue Q/Q | -100% |
Revenue Y/Y | 3.84% |
Profit margin | -1130.68% |
Oper. margin | -4913.93% |
Gross margin | 76.7% |
EBIT margin | -4913.93% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeVascular Biogenics Ltd. stock price history
Vascular Biogenics Ltd. stock forecast
Vascular Biogenics Ltd. financial statements
| Sep 2022 | 481K | -9.06M | -1884.62% |
|---|---|---|---|
| Dec 2022 | 113K | -3.25M | -2882.3% |
| Mar 2023 | 0 | 610K | |
| Jun 2023 | 0 | -874K |
| Sep 2022 | 35526000 | 10.22M | 28.77% |
|---|---|---|---|
| Dec 2022 | 29659000 | 7.20M | 24.3% |
| Mar 2023 | 28113000 | 8.21M | 29.22% |
| Jun 2023 | 24646000 | 5.40M | 21.95% |
| Sep 2022 | -6.82M | 10.03M | 22K |
|---|---|---|---|
| Dec 2022 | -6.72M | 5.99M | 0 |
| Mar 2023 | -1.68M | 10.1M | 0 |
| Jun 2023 | -2.36M | 186K | 1K |
Vascular Biogenics Ltd. alternative data
| Aug 2023 | 7 |
|---|---|
| Sep 2023 | 7 |
| Oct 2023 | 7 |
| Nov 2023 | 7 |
| Dec 2023 | 7 |
| Jan 2024 | 7 |
| Feb 2024 | 7 |
| Mar 2024 | 7 |
| Apr 2024 | 7 |
| May 2024 | 7 |
| Jun 2024 | 7 |
| Jul 2024 | 7 |
Vascular Biogenics Ltd. other data
0.50%
-3.22%
of VBLT is owned by hedge funds
10
-13
328.66K
-2.13M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Dec 2023 | 0 | 106856 |
| Jan 2024 | 0 | 50000 |
| Patent |
|---|
Application Filling date: 13 Apr 2020 Issue date: 16 Jun 2022 |
Application Filling date: 12 Mar 2020 Issue date: 19 May 2022 |
Application Filling date: 9 Sep 2021 Issue date: 28 Apr 2022 |
Grant Utility: Treatment methods using adenovirus Filling date: 23 Jul 2018 Issue date: 26 Apr 2022 |
Grant Filling date: 8 Jul 2019 Issue date: 7 Dec 2021 |
Application Filling date: 22 Oct 2018 Issue date: 21 Oct 2021 |
Application Filling date: 13 Oct 2020 Issue date: 1 Apr 2021 |
Application Filling date: 14 Sep 2020 Issue date: 18 Mar 2021 |
Application Filling date: 27 Aug 2020 Issue date: 11 Mar 2021 |
Application Filling date: 13 Mar 2019 Issue date: 31 Dec 2020 |
| Quarter | Transcript |
|---|---|
| Q1 2022 17 May 2022 | Q1 2022 Earnings Call Transcript |
| Q4 2021 23 Mar 2022 | Q4 2021 Earnings Call Transcript |
| Q3 2021 15 Nov 2021 | Q3 2021 Earnings Call Transcript |
| Q2 2021 16 Aug 2021 | Q2 2021 Earnings Call Transcript |
-
When is Vascular Biogenics Ltd.'s next earnings date?
Unfortunately, Vascular Biogenics Ltd.'s (VBLT) next earnings date is currently unknown.
-
Does Vascular Biogenics Ltd. pay dividends?
No, Vascular Biogenics Ltd. does not pay dividends.
-
How much money does Vascular Biogenics Ltd. make?
Vascular Biogenics Ltd. has a market capitalization of 12.11M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 14.32% to 658K US dollars.
-
What is Vascular Biogenics Ltd.'s stock symbol?
Vascular Biogenics Ltd. is traded on the NASDAQ under the ticker symbol "VBLT".
-
What is Vascular Biogenics Ltd.'s primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Vascular Biogenics Ltd.?
Shares of Vascular Biogenics Ltd. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Vascular Biogenics Ltd. have?
As Jul 2024, Vascular Biogenics Ltd. employs 7 workers.
-
When Vascular Biogenics Ltd. went public?
Vascular Biogenics Ltd. is publicly traded company for more then 10 years since IPO on 1 Oct 2014.
-
What is Vascular Biogenics Ltd.'s official website?
The official website for Vascular Biogenics Ltd. is vblrx.com.
-
How can i contact Vascular Biogenics Ltd.?
Vascular Biogenics Ltd. can be reached via phone at +972 8 993 5000.
Vascular Biogenics Ltd. company profile:
Vascular Biogenics Ltd.
vblrx.comExchange:
NASDAQ
Full time employees:
7
Industry:
Biotechnology
Sector:
Healthcare
Vascular Biogenics Ltd., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. Its programs are based on its vascular targeting system, a gene-based technology targeting newly formed blood vessels; and monocyte targeting technology, an antibody-based technology that enables specifically inhibit monocyte migration for immune-inflammatory applications. The company's lead product candidate is VB-111, a gene-based biologic that is in Phase III clinical trials for the recurrent platinum-resistant ovarian cancer; and Phase II clinical trials treatment of recurrent glioblastoma and colorectal cancer, as well as has completed Phase II clinical trial for the treatment of thyroid cancer. It is also developing VB-601 for various inflammatory indications, and VB-611 for various solid tumors. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was incorporated in 2000 and is headquartered in Modi'in, Israel.
8 HaSatat Street
Hevel Modi'in, 7178106
Hevel Modi'in, 7178106
CIK: 0001603207
ISIN: IL0012002452
CUSIP: M96883109
